KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Castle Biosciences (CSTL) Non-Current Receivables: 2018-2025

Historic Non-Current Receivables for Castle Biosciences (CSTL) over the last 7 years, with Sep 2025 value amounting to $2.0 million.

  • Castle Biosciences' Non-Current Receivables rose 85.35% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 85.35%. This contributed to the annual value of $918,000 for FY2024, which is 22.92% down from last year.
  • As of Q3 2025, Castle Biosciences' Non-Current Receivables stood at $2.0 million, which was up 81.10% from $1.1 million recorded in Q2 2025.
  • Castle Biosciences' 5-year Non-Current Receivables high stood at $2.0 million for Q3 2025, and its period low was $918,000 during Q4 2024.
  • Its 3-year average for Non-Current Receivables is $1.2 million, with a median of $1.1 million in 2025.
  • In the last 5 years, Castle Biosciences' Non-Current Receivables spiked by 101.38% in 2021 and then declined by 22.92% in 2024.
  • Castle Biosciences' Non-Current Receivables (Quarterly) stood at $1.3 million in 2021, then dropped by 16.90% to $1.1 million in 2022, then rose by 9.57% to $1.2 million in 2023, then decreased by 22.92% to $918,000 in 2024, then spiked by 85.35% to $2.0 million in 2025.
  • Its Non-Current Receivables stands at $2.0 million for Q3 2025, versus $1.1 million for Q2 2025 and $1.0 million for Q1 2025.